LCAT and chronic kidney disease: The uremic and inflammatory status are known to alter HDL lipid and protein composition; HDL from CKD patients present with reduced levels of apolipoprotein (apo)A-I, apoA-II, lecithin:cholesterol acyltransferase (LCAT) and paraoxonase, while pro-oxidant factors such as malondialdehyde, myeloperoxidase, and symmetric dimethylarginine are increased [7,10,11,12].